基於體學的臨床試驗市場規模、佔有率和成長分析：按體學類型、服務類型、階段、應用、技術、最終用戶和地區分類－2026-2033年產業預測

2024 年全球基於體學的臨床試驗市場價值為 87 億美元，預計到 2025 年將成長至 98.1 億美元，到 2033 年將成長至 257.2 億美元，在預測期（2026-2033 年）內複合年成長率為 12.8%。

受精準醫療需求日益成長的推動，基於體學的全球臨床試驗市場正經歷顯著成長。這種方法能夠根據分子特徵對患者進行分層，與傳統方法相比，顯著提高了臨床試驗的有效性。次世代定序等技術的進步拓展了分析能力，並支持了更精準的研究，從而提高了成功率，並減少了樣本大小和試驗週期。法律規範也日益支持生物標記主導的研究，促進了能夠同時評估多種突變的多基因檢測的應用。這些進步，加上單細胞RNA定序等技術，正在簡化臨床試驗流程，降低成本，並吸引投資。因此，製藥公司正利用這些優勢，促進良性創新循環，加速新療法的研發。

全球基於體學的臨床試驗市場促進因素

全球體學臨床試驗市場的主要促進因素之一是「個人化醫療」需求的日益成長，個人化醫療旨在根據個體的基因組、蛋白質組或代謝譜最佳化治療方案。基因組學、蛋白質組學和代謝體學等體學技術的進步使研究人員能夠理解複雜的生物過程，並識別能夠提高治療效果和安全性的生物標記。此外，慢性病盛行率的不斷上升以及對更具針對性的治療方法日益成長的需求，也推動了對體學研究的投資。因此，製藥和生物技術公司正擴大採用基於體學的調查方法來簡化藥物發現流程並改善患者預後。

全球體學臨床試驗市場面臨的限制因素

全球基於體學的臨床試驗市場面臨的主要限制因素之一是，將體學技術整合到傳統臨床試驗框架中高成本且複雜。這些先進技術，例如基因組學、蛋白質組學和代謝體學，需要專門的設備、熟練的人員以及對數據分析和管理系統的大量投資。這種複雜性導致試驗週期延長和運作成本增加，從而阻礙了小規模機構參與此類研究。此外，監管方面的挑戰以及體學數據標準化的需求也可能成為市場廣泛應用和成長的障礙。

全球基於體學的臨床試驗市場趨勢

在全球組體學技術進步的推動下，基於體學的臨床試驗市場正呈現與精準醫療顯著融合的趨勢。這種融合正在革新試驗設計，使申辦方能夠利用分子特徵有效地對患者群體進行分層，並實現對治療反應的即時監測。這些創新不僅加速了假設檢驗，還透過適應性方案最大限度地降低了脫落率，並增強了監管機構的信心。這種不斷發展的格局有助於更有效率地從早期研究過渡到後期檢驗，最終有助於在競爭激烈的環境中建立差異化的產品定位，使其成為現代臨床研究的關鍵要素。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢
• 價值鏈分析
• 案例研究
• 技術評估
• 客戶和採購標準分析
• 管道分析
• 疾病流行病學

全球基於體學的臨床試驗市場規模：按體學類型分類

• 基因組學
• 蛋白質體學
• 轉錄組學
• 代謝體學
• 表觀基因
• 多體學

全球基於體學的臨床試驗市場規模：按服務類型分類

• 生物標記發現
• 患者分層
• 樣品分析
• 生物資訊學和數據分析
• 臨床試驗管理
• 其他

全球基於體學的臨床試驗市場規模：按階段分類

• 第一階段
• 第二階段
• 第三階段
• 第四階段

全球基於體學的臨床試驗市場規模：按應用領域分類。

• 腫瘤學
• 神經病學
• 心血管疾病
• 感染疾病
• 罕見疾病
• 其他

全球基於體學的臨床試驗市場規模：按技術分類

• 次世代定序（NGS）
• 質譜分析
• PCR技術
• 微陣列
• 人工智慧和生物資訊學平台

全球基於體學的臨床試驗市場規模：按最終用戶分類

• 製藥公司
• 生技公司
• 受託研究機構（CRO）
• 學術研究機構

全球基於體學的臨床試驗市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• IQVIA
• Labcorp Drug Development
• ICON plc
• Parexel
• Thermo Fisher Scientific
• Syneos Health
• Medpace
• Charles River Laboratories
• Eurofins Scientific
• Tempus AI
• Illumina
• QIAGEN
• SOPHiA GENETICS
• Roche
• Natera
• Personalis
• Bio-Rad Laboratories
• DNAnexus
• Veracyte
• Guardant Health

結論與建議

Global Omics-Based Clinical Trials Market size was valued at USD 8.7 Billion in 2024 and is poised to grow from USD 9.81 Billion in 2025 to USD 25.72 Billion by 2033, growing at a CAGR of 12.8% during the forecast period (2026-2033).

The global market for omics-based clinical trials is experiencing significant growth driven by the rising demand for precision medicine. This approach allows for patient stratification based on molecular signatures, enhancing the effectiveness of clinical trials compared to traditional methods. Advances like next-generation sequencing have expanded analytical capabilities, enabling focused studies and improving success rates while reducing sample sizes and timelines. Regulatory frameworks are increasingly supportive of biomarker-driven research, promoting the use of multiplexed panels that can assess numerous alterations concurrently. These developments, coupled with technologies such as single-cell RNA sequencing, are streamlining trial processes, cutting costs, and attracting investment. Consequently, pharmaceutical firms are leveraging these advantages, fostering a cycle of innovation and expedited development of new therapies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Omics-Based Clinical Trials market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Omics-Based Clinical Trials Market Segments Analysis

Global omics-based clinical trials market is segmented by omics type, service type, phase, application, technology, end user and region. Based on omics type, the market is segmented into Genomics, Proteomics, Transcriptomics, Metabolomics, Epigenomics and Multi-Omics. Based on service type, the market is segmented into Biomarker Discovery, Patient Stratification, Sample Analysis, Bioinformatics & Data Analysis, Clinical Trial Management and Others. Based on phase, the market is segmented into Phase I, Phase II, Phase III and Phase IV. Based on application, the market is segmented into Oncology, Neurology, Cardiovascular Disorders, Infectious Diseases, Rare Diseases and Others. Based on technology, the market is segmented into Next-Generation Sequencing (NGS), Mass Spectrometry, PCR Technologies, Microarrays and AI & Bioinformatics Platforms. Based on end user, the market is segmented into Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations (CROs) and Academic & Research Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Omics-Based Clinical Trials Market

One key market driver for the global omics-based clinical trials market is the increasing demand for personalized medicine, which tailors treatments based on individual genetic, proteomic, or metabolic profiles. Advances in omics technologies, such as genomics, proteomics, and metabolomics, enable researchers to understand complex biological processes and identify biomarkers that can enhance the efficacy and safety of therapies. Moreover, the growing prevalence of chronic diseases and the need for more targeted therapeutic approaches are propelling investments in omics research. Consequently, pharmaceutical and biotechnology companies are increasingly adopting omics-based methodologies to streamline drug development processes and improve patient outcomes.

Restraints in the Global Omics-Based Clinical Trials Market

One of the key market restraints for the global omics-based clinical trials market is the high cost and complexity associated with integrating omics technologies into traditional clinical trial frameworks. These advanced technologies, which include genomics, proteomics, and metabolomics, require specialized equipment, skilled personnel, and significant investment in data analysis and management systems. This complexity can lead to longer trial timelines and increased operational costs, deterring smaller organizations from participating in such studies. Additionally, regulatory challenges and the need for standardization in omics data can create barriers to widespread adoption and growth in the market.

Market Trends of the Global Omics-Based Clinical Trials Market

The Global Omics-Based Clinical Trials market is experiencing a significant trend towards the integration of precision medicine, driven by advancements in omics technologies. This convergence is revolutionizing trial designs, allowing sponsors to effectively stratify patient cohorts using molecular signatures while enabling real-time monitoring of treatment responses. Such innovations not only enhance the speed of hypothesis testing but also minimize attrition rates and bolster regulatory confidence through adaptive protocols. This evolving landscape supports a more efficient transition from early-phase investigations to late-stage confirmations and ultimately aids in establishing differentiated product positioning amidst competitive therapeutic environments, making it a pivotal component of modern clinical research.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape
• Value Chain Analysis
• Case Studies
• Technology Assessment
• Customer & Buying Criteria Analysis
• Pipeline Analysis
• Disease Epidemiology

Global Omics-Based Clinical Trials Market Size by Omics Type & CAGR (2026-2033)

• Market Overview
• Genomics
• Proteomics
• Transcriptomics
• Metabolomics
• Epigenomics
• Multi-Omics

Global Omics-Based Clinical Trials Market Size by Service Type & CAGR (2026-2033)

• Market Overview
• Biomarker Discovery
• Patient Stratification
• Sample Analysis
• Bioinformatics & Data Analysis
• Clinical Trial Management
• Others

Global Omics-Based Clinical Trials Market Size by Phase & CAGR (2026-2033)

• Market Overview
• Phase I
• Phase II
• Phase III
• Phase IV

Global Omics-Based Clinical Trials Market Size by Application & CAGR (2026-2033)

• Market Overview
• Oncology
• Neurology
• Cardiovascular Disorders
• Infectious Diseases
• Rare Diseases
• Others

Global Omics-Based Clinical Trials Market Size by Technology & CAGR (2026-2033)

• Market Overview
• Next-Generation Sequencing (NGS)
• Mass Spectrometry
• PCR Technologies
• Microarrays
• AI & Bioinformatics Platforms

Global Omics-Based Clinical Trials Market Size by End User & CAGR (2026-2033)

• Market Overview
• Pharmaceutical Companies
• Biotechnology Companies
• Contract Research Organizations (CROs)
• Academic & Research Institutes

Global Omics-Based Clinical Trials Market Size & CAGR (2026-2033)

• North America (Omics Type, Service Type, Phase, Application, Technology, End User)
  • US
  • Canada
• Europe (Omics Type, Service Type, Phase, Application, Technology, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Omics Type, Service Type, Phase, Application, Technology, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Omics Type, Service Type, Phase, Application, Technology, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Omics Type, Service Type, Phase, Application, Technology, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• IQVIA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Labcorp Drug Development
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ICON plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Parexel
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Syneos Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medpace
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tempus AI
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SOPHiA GENETICS
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Natera
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Personalis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DNAnexus
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Veracyte
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guardant Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations